Clinical Trials Logo

Uterine Corpus Sarcoma clinical trials

View clinical trials related to Uterine Corpus Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04634617 Active, not recruiting - Clinical trials for Endometrial Carcinoma

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

Start date: January 9, 2020
Phase:
Study type: Observational

This trial studies pelvic floor dysfunction and quality of life in uterine cancer survivors. Using questionnaires may help researchers learn more about the sexual function and quality of life in uterine cancer survivors.

NCT ID: NCT03902379 Withdrawn - Clinical trials for Endometrial Carcinoma

Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer

Start date: July 27, 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer. Web-based intervention, such as coping and communication skills intervention, may help doctors to get a better understanding of ways to help gynecological cancer patients cope with their cancer experience.

NCT ID: NCT03422198 Recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

SAVE
Start date: January 30, 2018
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells. After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.